Text: H.R.1024 — 113th Congress (2013-2014)All Bill Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (03/07/2013)


113th CONGRESS
1st Session
H. R. 1024


To amend title XVIII of the Social Security Act to provide part D eligible individuals with single chronic diseases access to services under medication therapy management programs under the Medicare part D prescription drug program.


IN THE HOUSE OF REPRESENTATIVES

March 7, 2013

Mrs. McMorris Rodgers introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To amend title XVIII of the Social Security Act to provide part D eligible individuals with single chronic diseases access to services under medication therapy management programs under the Medicare part D prescription drug program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Medication Therapy Management Empowerment Act of 2013”.

SEC. 2. Access to services under medication therapy management programs for Medicare part D eligible individuals with single chronic diseases.

Section 1860D–4(c)(2)(A) of the Social Security Act (42 U.S.C. 1395w–104(c)(2)(A)) is amended—

(1) in clause (ii), by striking subclause (I) and inserting the following:

        “(I) have—

        “(aa) multiple chronic diseases (such as diabetes, asthma, hypertension, hyperlipidemia, and congestive heart failure); or

        “(bb) subject to clause (iii), any single chronic disease, including diabetes, hypertension, heart failure, dyslipidemia, respiratory disease (such as asthma, chronic obstructive pulmonary disease or chronic lung disorder), bone disease-arthritis (such as osteoporosis or osteoarthritis), rheumatoid arthritis, or mental health disorder (such as depression, schizophrenia, or bipolar disorder).”; and

(2) by adding at the end the following:

    “(iii) DETERMINATIONS RELATING TO PROGRAM COSTS FOR INCLUDING INDIVIDUALS WITH SINGLE CHRONIC DISEASES.—

    “(I) INITIAL DETERMINATIONS.—With regard to any single chronic disease, clause (ii)(I)(bb) shall only be applied if the Chief Actuary for the Centers for Medicare & Medicaid Services determines that the application of such clause with regard to such disease is not projected to increase overall costs to the Medicare program under this title over the five year period beginning on the date of determination.

    “(II) REVIEW OF DETERMINATIONS.—In the case that clause (ii)(I)(bb) is applied with respect to a single chronic disease pursuant to a determination under subclause (I), not later than five years after such date of determination, the Chief Actuary for the Centers for Medicare & Medicaid Services shall review the effect of the application of such clause with respect to such disease on the actual cost of the Medicare program under this title during such five years. Based on such review, if the Chief Actuary is unable to determine that, with regard to such single chronic disease, the application of such clause did not increase costs to the Federal government under the Medicare program under this title over such period, then the Secretary shall review the findings of the Chief Actuary and determine whether such clause shall continue to be applied with regard to such single chronic disease. In conducting such review and making such determination, the Secretary shall consider the extent to which the application of such clause with regard to such single chronic disease effects the health outcomes of part D eligible individuals and any savings and costs to the Federal government under the Medicare program under this title.”.